home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410d.zip
/
M94A0716.TXT
< prev
next >
Wrap
Text File
|
1994-10-21
|
3KB
|
42 lines
Document 0716
DOCN M94A0716
TI HIV vaccines.
DT 9412
AU Corey L; McElrath J; Kent S; Greenberg P; University of Washington,
Seattle.
SO Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:22 (abstract no.
FPI-1). Unique Identifier : AIDSLINE ASHM5/94348939
AB To date the NIAID sponsored AIDS Vaccine Evaluation Group (AVEU) has
enrolled over 1000 patients into Phase I/II clinical trials of candidate
HIV vaccines. 8 different envelope products have been evaluated
including two gp160 preparations, two subunit gp120 products, one yeast
derived gp120, one vaccinia gp160, 1 canarypox gp160, and one envelope
peptide based vaccine. All the vaccines have been immunogenic and
adverse effects have been limited to transient local reactions. Direct
comparison of immune responses is not possible in all cases due to
varying stages of development, the varying doses of vaccine and the
different adjuvants employed in the products. Overall, the two gp120
products have proven to elicit the highest neutralising antibody titers
among health seronegative vaccines. Over 90% of recipients receiving a
0, 1, 6 month regimen have detectable neutralising responses; the mean
neutralising titer average about 1:100, about 5-fold lower than that
seen with persons with naturally acquired HIV infection. T cell
lymphoproliferative responses are elicited by all of these vaccines
However, none of the subunit vaccines alone have elicited detectable
CD8+ cytolytic activity to HIV envelope (0 of 40 tested). However, 2 of
8 vaccinia naive individuals who have received a regimen consisting of
priming with a vaccinia recombinant and boosting with a gp160 subunit
protein have had detectable persistent CD8+ CTLs. A detailed description
of the above Phase I and II trials will be given.
DE Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION & CONTROL
AIDS Vaccines/*ADMINISTRATION & DOSAGE/IMMUNOLOGY Human HIV
Antibodies/BIOSYNTHESIS HIV Envelope Protein gp120/ADMINISTRATION &
DOSAGE/IMMUNOLOGY HIV Infections/IMMUNOLOGY/*PREVENTION & CONTROL
Immunization Schedule Vaccines, Synthetic/ADMINISTRATION &
DOSAGE/IMMUNOLOGY CLINICAL TRIAL CLINICAL TRIAL, PHASE I CLINICAL
TRIAL, PHASE II MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).